News stories about OptiNose (NASDAQ:OPTN) have been trending somewhat positive recently, according to Accern. The research firm scores the sentiment of news coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. OptiNose earned a news sentiment score of 0.08 on Accern’s scale. Accern also assigned news headlines about the company an impact score of 47.7511261271692 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
NASDAQ OPTN opened at $23.80 on Friday. The company has a debt-to-equity ratio of 0.57, a quick ratio of 9.50 and a current ratio of 9.66. OptiNose has a 12-month low of $15.01 and a 12-month high of $25.74. The company has a market cap of $904.57 million and a price-to-earnings ratio of -4.23.
Get OptiNose alerts:
OptiNose (NASDAQ:OPTN) last released its earnings results on Monday, May 14th. The company reported ($0.81) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.74) by ($0.07). The business had revenue of $0.87 million during the quarter. equities research analysts forecast that OptiNose will post -3.3 EPS for the current year.
Several research firms have issued reports on OPTN. Zacks Investment Research upgraded OptiNose from a “sell” rating to a “hold” rating in a research report on Wednesday, May 16th. ValuEngine upgraded OptiNose from a “sell” rating to a “hold” rating in a research report on Wednesday, May 2nd. Two investment analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average target price of $29.25.
In other OptiNose news, CEO Peter K. Miller bought 5,054 shares of the company’s stock in a transaction on Friday, March 16th. The shares were bought at an average price of $18.58 per share, for a total transaction of $93,903.32. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Insiders own 67.80% of the company’s stock.
OptiNose Company Profile
OptiNose, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, and throat; and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary optinose exhalation delivery system that delivers a topically-acting and potent anti-inflammatory corticosteroid for the treatment of chronic rhinosinusitis with and without nasal polyps.